Brokerages Expect Evoke Pharma Inc (NASDAQ:EVOK) to Announce -$0.07 EPS

Brokerages predict that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings of ($0.07) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.10) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 30%. The business is expected to issue its next quarterly earnings report on Wednesday, March 4th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.35) per share for the current year. For the next fiscal year, analysts anticipate that the company will post earnings of ($0.19) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02.

A number of research analysts have commented on the stock. Zacks Investment Research downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research report on Monday.

NASDAQ:EVOK opened at $1.59 on Friday. Evoke Pharma has a 1-year low of $0.50 and a 1-year high of $3.26. The company has a 50-day moving average of $1.07 and a 200 day moving average of $0.89.

A hedge fund recently bought a new stake in Evoke Pharma stock. Marshall Wace LLP purchased a new position in Evoke Pharma Inc (NASDAQ:EVOK) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 92,406 shares of the specialty pharmaceutical company’s stock, valued at approximately $139,000. Marshall Wace LLP owned approximately 0.40% of Evoke Pharma at the end of the most recent quarter. 6.57% of the stock is owned by institutional investors.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Featured Story: How dollar cost averaging works

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.